Live biotherapeutic product exhibits similar efficacy and superior engraftment to same donor fecal microbiota transplant for recurrent Clostridioides difficile infection
Bethlehem, L.; Bartu, L.; Marke, G.; Mar, P.; Feldman, S.; Eggers, J.; Ruprecht, C.; Britton, G.; Aggarwala, V.; Bongers, G.; Li, Z.; Yang, N.; Hohmann, E.; Mogno, I.; Faith, J. J.; Grinspan, A.
Show abstract
Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridioides difficile infection (rCDI) but has undefined composition and poor scalability. In vitro manufactured live biotherapeutic products (LBP) enable both scalability and defined strain composition but with higher manufacturing complexity, resulting in few LBP trials. We developed an accessible platform to produce human-grade LBPs. We provide regulatory documentation and manufacturing protocols to facilitate translating microbiome advances to human trials. With this platform, we conduct the first direct comparison of the same bacterial strains administered after in vitro manufacturing (LBP) compared to donor sourced (FMT) across two doses. In a phase 1b trial (n=18), an endoscopic dose of the 15-strain consortium MTC01 was safe with rCDI prevention eight weeks after dosing in seven out of nine LBP patients, similar to eight out of nine FMT patients. Notably, MTC01 strain engraftment was superior to FMT at higher doses.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness 91%
- Machine Learning-Based Prediction of Pediatric Ulcerative Colitis Treatment Response using Diagnostic Histopathology 91%
- Early-life microbial intervention reduces colitis risk promoted by antibiotic-induced gut dysbiosis 90%
Similar papers in this journal
- High-density microbioreactor process designed for automated point-of-care manufacturing of CAR T cells 90%
- Nutritional deficiency recapitulates intestinal injury associated with environmental enteric dysfunction in patient-derived Organ Chips 89%
- Molecular de-extinction of antibiotics enabled by deep learning 88%
Similar papers in this journal
- Primary human colonic mucosal barrier crosstalk with super oxygen-sensitive Faecalibacterium prausnitzii in continuous culture 92%
- Real-time analysis of a mass vaccination effort via an Artificial Intelligence platform confirms the safety of FDA-authorized COVID-19 vaccines 90%
- FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system 89%
Similar papers in this journal
- Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens 92%
- A metagenomic DNA sequencing assay that is robust against environmental DNA contamination 92%
- Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites 92%
Similar papers in this journal
- Intraspecies strain exclusion, antibiotic pretreatment, and donor selection control microbiota engraftment after fecal transplantation 91%
- Antibody therapy reverses biological signatures of COVID-19 progression 91%
- In mouse and in vitro models, bowel preparation promotes pathogen colonization, translocation and exacerbation of inflammation 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.